Cost effectiveness of tolvaptanBMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d1947 (Published 29 March 2011) Cite this as: BMJ 2011;342:d1947
- Paul Grant, physician
- 1Department of Endocrinology, King’s College Hospital, London SE5 9RS, UK
Amin and Meeran refer to the relative expense of tolvaptan, one of the new vasopressin 2 receptor antagonists.1 They suggest that it has little benefit over existing treatments but fail to mention …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial